Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab Systemic Therapy with TACE/HAIC for Conversion of Unresectable Intermediate–Advanced HCC
ChiCTR2500109875Phase 3Not yet recruiting
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Sep 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of iparomlimab, tuvonralimab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by First Affiliated Hospital of Bengbu Medical University. Primary endpoints: Rate of conversion to resectability and Degree of tumor shrinkage. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500109875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109875.